Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
|Articles|August 12, 2016
Pharmacy Week in Review: August 12, 2016
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Advertisement
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more. Our Week in Review is a can’t miss for the busy pharmacy professional.
Advertisement
Related to this article
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Pharmacists make a difference in patients’ lives through MTM services.
The Main Street Pharmacy Access Act would let Medicare pay pharmacists for care they can already legally provide, if pharmacies have the time.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Finerenone Expands MRA Options as Pharmacists Address Underrecognized HFpEF
2
Researchers Target Viral Fusion for Universal Flu, HIV Vaccines
3
Diuretics, eGFR, and Intensive BP Lowering in CKD: What to Watch
4
Finerenone in Heart Failure: Evidence and Practice a Year Later
5